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AmyotrophicLateralSclerosis (ALS) is a fatal neurodegenerative disease, characterized by 
degeneration of upper and lowermotorneurons (MNs) (Brown, 1995). The mechanisms of 
neuronaldeath in ALS are stilllargelyobscure and theyhavebeenascribed to severalcellular and 
molecularalterationsthatalsoinvolved non neuronalcellssuchasastrocytes and microglia (Ilieva 
et al., 2009).In line with this, itiswellknownthatGlutamate (Glu)-mediatedexcitotoxicityplays a 
major role in the degeneration of motorneurons (Vucic et al., 
2014).Severalevidenceshavealreadydemonstratedthatbothexcessiveneuronal Glu release and 
defectiveglial Glu uptakecontribute to increment the extracellular Glulevel (Rothstein et al., 
1995; Milanese et al., 2011; Giribaldi et al., 2013), contributing to motorneurondeath. 
In this scenario, wehavepreviouslystudied the molecularmechanismssustaining the 
excessiveexocytoticGlu release from the spinalcordnerveendings (synaptosomes) in SOD1G93A 
mice, a transgenic mouse model of human ALS (Gurney et al., 1994),at the late stage of the 
disease (Milanese te al., 2011). Thus, herein,westudied the mechanismsunderlying Glu release 
in spinalcordsynaptosomes of SOD1G93A mice at a presymptomaticdisease stage (30 days) in 
order to definehowthisphenomenonoccursduringALSprogression. 
Firstly, by release experiments, wefoundthat the basal release of Glu was more elevated in the 
spinalcord of SOD1G93Amice with respect to age-matchedSOD1 control mice, and that the 
surplus of release relied on synapticvesicleexocytosis. Exposure tohigh KCl or 
ionomycinprovoked Ca2+-dependent Glu release thatwaslikewiseaugmented in 
SOD1G93Amice.Equally, the Ca2+-independenthypertonicsucroseinducedhigher Glu release in 
SOD1G93Amicethan in age-matchedcontrols. Also in this case, the surplus of Glu 
releasewasexocytotic in nature. Studyingwhichmolecularmechanismsare able to sustain the 
abovedescribedabnormal Glu release, 
wefoundelevatedcytosolicCa2+levelsaswellasincreasedphosphorylation of Synapsin-I, 
whichwascausallyrelated to the abnormal Glu releasemeasured in spinalcordsynaptosomes of 
pre-symptomatic SOD1G93A mice, and increasedphosphorylation ofglycogensynthase kinase-3 
at the inhibitorysites, an eventthatfavours SNARE proteinassembly, by using FURA dye and 
Western blotting, respectively. Moreover, Western blotexperimentsrevealed an 
increasednumber of SNARE proteincomplexesat the nerve terminal membrane,with no changes 
of the three SNARE proteins (VAMP, SNAP 25 and Syntaxin) and increasedexpression of 
synaptotagmin-1 and β-Actin, butnot of an array of other release-relatedpresynapticproteins 
(synaptophysin, munch-18, munch-13, rab2A, complexin 1/2, NSF, α/β snap, dynamin, synapsin-I, 
and myosin). Finally, the abnormal Glu release wasnormalized by entrappingsynaptosomes with 
specificantobodies for Synapsin-I phosphorilationsites, confirming the massiverole of 
thisprotein in the excessive Glu releaseat the pre-syntomatic stage of the disease. 
In conclusion, theseresults indicate that the abnormalexocytoticGlu release occurs inthe 
spinalcord of pre-symptomatic SOD1G93A mice and itismainlybased on the increasedsize of the 
readilyreleasable pool of vesicles and release facilitation, supported by plasticchanges of 
specificpre-synapticmechanisms.Hence, thesemechanismsmightrepresent a keyfeature and 
play a pivotalrole in the development of the disease. 
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